SightGlass Vision Highlights New Myopia Control Spectacle Lens Technology at COOC 2023
Companies Present Enhanced Lenses, Key Trials Results and Case Reviews in Collaboration with Top Chinese Eye Care Professionals
LOS ALTOS, CALIF., April 12, 2023—SightGlass Vision will share its innovative myopia control spectacle lens technology at the International Congress of Ophthalmology and Optometry China (COOC), in partnership with Nikon Lenswear. The conference takes place in Shanghai from April 14-16, 2023, attracting the country’s most prominent eye care clinicians, researchers, and educators.
Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy1,2,3 made its commercial debut in several markets, including China. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.
During COOC, SightGlass Vision and Nikon Lenswear will demonstrate the latest lens iteration, featuring enhanced aesthetics that make the micro-dots less visible during everyday wear. In addition, Marcella McParland and Lucill Wang from the SightGlass Vision Clinical, Medical and Professional Affairs team will present side by side with several ophthalmology key opinion leaders, including Dr. Peter Chen from Shanghai ENT and Dr. Liu Longqian from West China Center of Medical Sciences of Sichuan University, to present multiple case reviews and explain results from its multi-year CYPRESS clinical trial. The company has also begun a separate clinical trial in China.
“Since our launch with Nikon in China several months ago, momentum has continued to grow,” said Andrew Sedgwick, CEO of SightGlass Vision. “No other country has the depth of understanding and awareness of myopia’s impact on society as China, nor the experience of its clinical community with the disease. Our introduction of new, evidence-based Diffusion Optics TechnologyTM to help reach aneven larger segment of children has been widely embraced—something we expect to see first-hand
at COOC.”
The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people—half the world’s population—will be myopic by 2050. 4 Uncorrected myopia is the leading cause of visual impairment in children. Over time, its progression may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia5.
In addition to China, spectacle lenses with Diffusion Optics Technology are currently available in the Netherlands and Israel, as well as through preliminary market trials in other countries. For more information, visit SightGlassVision.com.
For more information, visit SightGlassVision.com.
About SightGlass Vision
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics TechnologyTM is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.
SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States.
Media Contact
Mike McDougall, APR, Fellow PRSA,
FAAO McDougall Communications for SightGlass Vision
+1-585-434-2150 or mike@mcdougallpr.com
REFERENCES
1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published. Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005
2 Joe Rappon, Jay Neitz, Maureen Neitz, Carol Chung, Thomas Walter Chalberg; Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408
3 A 36-month clinical trial demonstrated safety and efficacy for children ages six to 10 at enrolment, significantly reducing both axial length and cycloplegic SER progression versus the control. The study has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, three-arm parallel group clinical trial with diverse subjects reflecting the U.S. population. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.
4 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-42
5 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363
Please note that our products are not available for sale or distribution in every country in the world.
Our products are not available for sale in the U.S.